Abbott seeks appeal on royalties to UK's Cambridge
Tuesday, 15 February, 2005
Abbott Laboratories is seeking to appeal a British court ruling that granted Cambridge Antibody Technology a greater percentage of royalties on Abbott's arthritis drug Humira.
In December, UK Judge Hugh Laddie said Abbott should pay Cambridge a royalty of just over 5 per cent on sales of Humira, compared with the royalty of 2 per cent of net sales it has been paying.
The application will be considered by one Court of Appeal judge, Cambridge said in a statement. If the application is unsuccessful, Abbott will be entitled to request a hearing.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
